Physician profile
Steven Yoon
NPI 1215138110
$2,603.88
in general payments reported to CMS, 2019-2025
18 companies · $655 in 2025
The $655 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $135 · 2021: $171 · 2022: $204 · 2023: $230 · 2024: $582 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,466.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $682.64 | 2024-2025 | Xdemvy |
| Amgen INC. | $497.48 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $331.06 | 2019-2022 | |
| Horizon Therapeutics Plc | $297.72 | 2021-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $166.29 | 2019-2021 | |
| Allergan, INC. | $120.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $101.93 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $101.32 | 2019 | |
| Shire North American Group INC | $83.12 | 2019 | |
| Abbvie INC. | $69.68 | 2022-2023 | Durysta |
| Alcon Vision LLC | $26.98 | 2020 | |
| Oyster Point Pharma, INC. | $21.72 | 2022 | |
| Biotissue Holdings INC. | $20.06 | 2025 | |
| Thea Pharma INC. | $20.04 | 2024 | Iyuzeh |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $16.64 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Akorn, INC. | $14.34 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $12.90 | 2023 | Lipiflow System Activator (Disposable) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.